Anti-tuberculosis drug-induced liver injury in patient with hepatitis B and cirrhosis: A case report
Rusdi Zakki Aminy, Ulfa Kholili
Annals of Medicine and Surgery · 2022-07
Abstract
Background: Pulmonary tuberculosis patients infected with hepatitis B are at high risk for drug-induced liver injury. Case presentation: A 42-year-old Indonesian female complained of sclera icterus, tea-colored urine, vomiting, dyspnea, and swollen stomach and legs. The patient experienced this condition after taking anti-tuberculosis drugs for five days. Her medical history showed hepatitis B and cirrhosis. Follow-up examination included chest X-ray and GeneXpert supported a diagnosis of pulmonary tuberculosis. However, abdominal ultrasonography indicated ascites and cirrhosis. We diagnosed the patient with anti-tuberculosis DILI, cirrhosis Child-Pugh C (score 12) related to hepatitis B, and pulmonary tuberculosis. We decided to stop the anti-tuberculosis drug. We treated the patient using tenofovir, hepatoprotective drug, diuretics, and albumin infusion. On the third day, the patient received new anti-tuberculosis drugs, including levofloxacin 750 mg, ethambutol 1000 mg, and streptomycin 1000 mg (LES). The patient's condition then gradually improved. Discussion: The dilemma of treating tuberculosis in liver disease is treating tuberculosis without ignoring hepatitis B and cirrhosis. Conclusion: Administration of anti-tuberculosis drugs based on liver tolerance of hepatotoxic drug in patients with hepatitis B and cirrhosis.
MeSH terms
- Medicine
- Ethambutol
- Cirrhosis
- Tuberculosis
- Hepatitis B
- Internal medicine
- Gastroenterology
- Hepatitis
- Pyrazinamide
- Hepatitis C
- Surgery